ClinicalTrials.gg

Program

ivacaftor

Also written as “IVA”, “Ivacaftor” and “ELX/TEZ/IVA”.

Its studies are mostly in Cystic Fibrosis · Ciliary Motility Disorders, led by 3 companies.

Furthest: phase 4, since Aug 15, 201678 company-led studies, 4 open or runningNext primary completion: Apr 6, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Vertex Pharmaceuticals744 open or runningphase 4since Aug 15, 2016Apr 5, 2007Apr 6, 2027phase 3 · NCT05331183
Sun Pharmaceutical Industries30 open or runningphase 1since Mar 5, 2015Mar 5, 2015none ahead
Parion Sciences10 open or runningphase 2since Aug 12, 2016Aug 12, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 47 studies since Oct 8, 2012.

  1. Aug 28, 2020Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT04537793 · 83 enrolled · United States, Australia, Canada and more
  2. Sep 3, 2020Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT04545515 · 120 enrolled · Australia, Canada, Denmark and more
  3. Oct 21, 2020Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT04599465 · 69 enrolled · Australia, Belgium, Czechia and more
  4. Jul 9, 2021Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT04969224 · 82 enrolled · Australia, Belgium, Canada and more
  5. Oct 27, 2021Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05111145 · 86 enrolled · Australia, Belgium, Canada and more
  6. Nov 29, 2021Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05153317 · 71 enrolled · United States, Australia, Canada and more
  7. Mar 1, 2022Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05274269 · 307 enrolled · Austria, Belgium, Canada and more
  8. Apr 8, 2022Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05331183 · 297 enrolled · Austria, Belgium, Canada and more
  9. May 19, 2023Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05882357 · 67 enrolled · Australia, Canada, Denmark and more
  10. Nov 23, 2023Phase 1 study in Cystic FibrosisVertex Pharmaceuticals · NCT06154447 · 165 enrolled · United States
  11. Jun 10, 2024Phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT06460506 · 50 enrolled · Australia, Canada, Denmark and more
  12. Dec 4, 2025Phase 1 study in Cystic FibrosisVertex Pharmaceuticals · NCT07283770 · 152 planned · United States
  13. Feb 20, 2026Phase 1 study in Cystic FibrosisVertex Pharmaceuticals · NCT07437105 · 160 planned · United States
  14. Oct 19, 2026Primary completion moved from 2026-11-19 to 2027-07-12Date moved laterphase 1 · +8 months · NCT07283770

Ahead

  1. Apr 6, 2027Primary completion: phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT05331183
  2. Jun 26, 2027Primary completion: phase 1 study in Cystic FibrosisVertex Pharmaceuticals · NCT07437105
  3. Jul 12, 2027Primary completion: phase 1 study in Cystic FibrosisVertex Pharmaceuticals · NCT07283770
  4. Sep 30, 2027Primary completion: phase 3 study in Cystic FibrosisVertex Pharmaceuticals · NCT06460506

TargetBeta

CFTR →read by rule
“Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator activator”ChEMBL 37, by rule

Other programs on CFTR

ProgramCompanyFurthest phaseStudies
lumacaftorruleVertex Pharmaceuticalsphase 423
tezacaftorruleVertex Pharmaceuticalsphase 339

Studies

The newest 60 of 78 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07437105Cystic Fibrosis · United States1RecruitingVertex PharmaceuticalsJun 26, 2027160
NCT07283770Cystic Fibrosis · United States1RecruitingVertex PharmaceuticalsJul 12, 2027152
NCT06460506Cystic Fibrosis · Australia, Canada, Denmark and more3Active, not recruitingVertex PharmaceuticalsSep 30, 202750
NCT06154447Cystic Fibrosis · United States1CompletedVertex PharmaceuticalsJul 10, 2026165
NCT05882357Cystic Fibrosis · Australia, Canada, Denmark and more3CompletedVertex PharmaceuticalsSep 4, 202567
NCT05331183Cystic Fibrosis · Austria, Belgium, Canada and more3Active, not recruitingVertex PharmaceuticalsApr 6, 2027297
NCT05274269Cystic Fibrosis · Austria, Belgium, Canada and more3CompletedVertex PharmaceuticalsJul 5, 2023307
NCT05153317Cystic Fibrosis · United States, Australia, Canada and more3CompletedVertex PharmaceuticalsJan 29, 202671
NCT05111145Cystic Fibrosis · Australia, Belgium, Canada and more3CompletedVertex PharmaceuticalsDec 20, 202286
NCT04969224Cystic Fibrosis · Australia, Belgium, Canada and more3CompletedVertex PharmaceuticalsJul 26, 202282
NCT04599465Cystic Fibrosis · Australia, Belgium, Czechia and more3CompletedVertex PharmaceuticalsJul 14, 202269
NCT04545515Cystic Fibrosis · Australia, Canada, Denmark and more3CompletedVertex PharmaceuticalsMar 24, 2023120
NCT04537793Cystic Fibrosis · United States, Australia, Canada and more3CompletedVertex PharmaceuticalsJun 3, 202283
NCT04362761Cystic Fibrosis · Australia, Belgium, Germany and more3CompletedVertex PharmaceuticalsDec 21, 2022172
NCT04353817Cystic Fibrosis · Australia, Canada, Denmark and more3CompletedVertex PharmaceuticalsMay 17, 2021121
NCT04235140Cystic Fibrosis · United States, Canada3CompletedVertex PharmaceuticalsAug 22, 202352
NCT04183790Cystic Fibrosis · United States, Australia, Canada and more3CompletedVertex PharmaceuticalsFeb 24, 202464
NCT04058366Cystic Fibrosis · United States, Australia, Belgium and more3CompletedVertex PharmaceuticalsDec 16, 2022251
NCT03911713Cystic Fibrosis · United States, Australia, Belgium and more2CompletedVertex PharmaceuticalsAug 20, 202077
NCT03768089Cystic Fibrosis · Netherlands, United Kingdom2CompletedVertex PharmaceuticalsMay 3, 2019115
NCT03691779Cystic Fibrosis · United States, Australia, Canada and more3CompletedVertex PharmaceuticalsAug 7, 202071
NCT03625466Cystic Fibrosis · Germany2CompletedVertex PharmaceuticalsOct 9, 202051
NCT03633526Cystic Fibrosis · United States3TerminatedVertex PharmaceuticalsJan 18, 201918
NCT03601637Cystic Fibrosis · United States, Canada3CompletedVertex PharmaceuticalsOct 29, 202161
NCT03559062Cystic Fibrosis · Australia, Belgium, Denmark and more3CompletedVertex PharmaceuticalsDec 21, 201867
NCT03537651Cystic Fibrosis · United States, Australia, Belgium and more3CompletedVertex PharmaceuticalsOct 28, 2020130
NCT03486236Cystic Fibrosis · United Kingdom1CompletedVertex PharmaceuticalsSep 14, 201616
NCT03277196Cystic Fibrosis · United States, Australia, Canada and more3CompletedVertex PharmaceuticalsOct 2, 202386
NCT03224351Cystic Fibrosis · United States, Ireland, Israel and more2CompletedVertex PharmaceuticalsFeb 28, 2018124
NCT03150719Cystic Fibrosis · United States, France, Germany3CompletedVertex PharmaceuticalsAug 9, 201898
NCT03125395Cystic Fibrosis · United States, Canada3CompletedVertex PharmaceuticalsJul 17, 201957
NCT03068312Cystic Fibrosis · Israel3CompletedVertex PharmaceuticalsDec 18, 201838
NCT03061331Cystic Fibrosis · Netherlands2CompletedVertex PharmaceuticalsSep 6, 201720
NCT02971839Cystic Fibrosis · United States2TerminatedVertex PharmaceuticalsAug 201711
NCT02951195Cystic Fibrosis · United States2CompletedVertex PharmaceuticalsJan 201880
NCT02951182Cystic Fibrosis · United States, Australia, Austria and more2CompletedVertex PharmaceuticalsAug 201774
NCT02875366Cystic Fibrosis · Australia, United Kingdom4CompletedVertex PharmaceuticalsSep 201770
NCT02871778Ciliary Motility Disorders · United States, Canada, Denmark and more2CompletedParion SciencesNov 20, 2018123
NCT02742519Cystic Fibrosis · Australia, Canada, United Kingdom3TerminatedVertex PharmaceuticalsAug 201714
NCT02730208Cystic Fibrosis · Australia2CompletedVertex PharmaceuticalsJul 201841
NCT02725567Cystic Fibrosis · United States, Australia, Canada and more3CompletedVertex PharmaceuticalsJun 28, 202257
NCT02680249Healthy · Australia1CompletedSun Pharmaceutical IndustriesApr 201615
NCT02599792Healthy · Australia1CompletedSun Pharmaceutical IndustriesApr 201637
NCT02565914Cystic Fibrosis · United States, Australia, Austria and more3CompletedVertex PharmaceuticalsMay 20191,131
NCT02544451Cystic Fibrosis · United States, Australia, Belgium and more3CompletedVertex PharmaceuticalsAug 2018246
NCT02516410Cystic Fibrosis · United States, Australia, Austria and more3CompletedVertex PharmaceuticalsJun 7, 2016168
NCT02514473Cystic Fibrosis · United States, Australia, Belgium and more3CompletedVertex PharmaceuticalsSep 2016206
NCT02508207Cystic Fibrosis · United States2CompletedVertex PharmaceuticalsJun 201734
NCT02412111Cystic Fibrosis · United States, Australia, Austria and more3CompletedVertex PharmaceuticalsSep 2017156
NCT02392234Cystic Fibrosis · United States, Australia, Belgium and more3CompletedVertex PharmaceuticalsFeb 2017248
NCT02392702Healthy · Australia1CompletedSun Pharmaceutical IndustriesJun 201515
NCT02347657Cystic Fibrosis · United States, Canada, Denmark and more3CompletedVertex PharmaceuticalsJan 20, 2017510
NCT02015507Cystic Fibrosis1CompletedVertex PharmaceuticalsFeb 201434
NCT01946412Cystic Fibrosis · United States, Canada, United Kingdom3CompletedVertex PharmaceuticalsDec 201533
NCT01931839Cystic Fibrosis · United States, Australia, Austria and more3CompletedVertex PharmaceuticalsApr 20161,164
NCT01807949Cystic Fibrosis · United States, Australia, Austria and more3CompletedVertex PharmaceuticalsApr 2014563
NCT01807923Cystic Fibrosis · United States, Australia, Canada and more3CompletedVertex PharmaceuticalsApr 2014559
NCT01768663Cystic Fibrosis · United States1CompletedVertex PharmaceuticalsSep 201380
NCT01707290Cystic Fibrosis · United States, Belgium, France and more3CompletedVertex PharmaceuticalsApr 2016125
NCT01705145Cystic Fibrosis · United States, Canada, United Kingdom3CompletedVertex PharmaceuticalsMar 201435

How it is read

Names in the registry

  • “IVA”, 26 entries
  • “Ivacaftor”, 26 entries
  • “ELX/TEZ/IVA”, 14 entries
  • “VX-770”, 10 entries
  • “LUM/IVA”, 8 entries

Codes read as this program: VX770.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.